Malin Johannesson

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease

Linda Söderberg, Malin Johannesson, Patrik Nygren et al. · Neurotherapeutics · 2022 · 413 citations · Full text

Life Sciences, Pharmacology, Dementia +15

Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice

Veronica Lindström, Therese Fagerqvist, Eva Nordström et al. · Neurobiology of Disease · 2014 · 134 citations · Full text

Life Sciences, Neurobiology, Neuroscience +7

Expression of 15-lipoxygenase type-1 in human mast cells

M. Gulliksson, Åsa Brunnström, Malin Johannesson et al. · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · 2007 · 63 citations

Life Sciences, Cell Biology, Immunology +13

ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease

Eva Nordström, Fredrik Eriksson, Jessica Sigvardson et al. · Neurobiology of Disease · 2021 · 54 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities

Linda Söderberg, Malin Johannesson, Eleni Gkanatsiou et al. · Scientific Reports · 2024 · 52 citations · Full text

Medicine, Neurology, Neuroscience +17